Please wait while the formulary information is being retrieved.
CETROTIDE (CETRORELIX ACETATE)
- Prevention of LH surge in ovarian hyperstimulation
0.25 mg subcutaneous kit
- Inject 0.25 mg by subcutaneous route once daily
Prevention of LH surge in ovarian hyperstimulation
- Inject 0.25 mg by subcutaneous route once daily
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Pregnancy
- Severe renal impairment
Contraindicated
- None
Severe
Moderate
- None
CETROTIDE (CETRORELIX ACETATE)
- Prevention of LH surge in ovarian hyperstimulation
- None
- None
More Frequent
Severe
Less Severe
- Ovarian hyperstimulation syndrome
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Hypersensitivity drug reaction
Less Severe
- Headache disorder
- Injection site sequelae
- Nausea
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Cetrorelix, Ganirelix
No relevant indication for use in children.
- 1 Day – 18 Years
- No relevant indication for use in children.
Cetrorelix
- Severity Level:
X
- Additional Notes:
Contraindicated
Cetrorelix
Not recommended by manufacturer
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Not recommended by manufacturer |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Prevention of LH surge in ovarian hyperstimulation | |
| Z31.83 | Encounter for assisted reproductive fertility procedure cycle |
| Z31.89 | Encounter for other procreative management |
| 0-9 | A-Z |
|---|---|
| Z31.83 | Encounter for assisted reproductive fertility procedure cycle |
| Z31.89 | Encounter for other procreative management |
Formulary Reference Tool